Cyfra 21-1 Lung Cancer Marker Serum

• Test Name: Cyfra 21-1 Lung Cancer Marker Serum Test
• Test Type: Tumor marker test
• Specimen Required: Blood sample (serum)
• Methodology: Enzyme-linked immunosorbent assay (ELISA) or chemiluminescent immunoassay (CLIA)
• Purpose: Measures the levels of Cyfra 21-1, a fragment of cytokeratin 19, in the serum, which is elevated in certain types of lung cancer, particularly non-small cell lung cancer (NSCLC).

• Diagnosis: Assists in the diagnosis of non-small cell lung cancer (NSCLC) by detecting elevated levels of Cyfra 21-1 in the blood.
• Prognosis: Provides information on the prognosis of lung cancer patients, with higher levels often indicating more advanced disease.
• Monitoring: Used to monitor treatment response and disease progression in patients with lung cancer, particularly NSCLC.
• Recurrence Detection: Helps in the early detection of lung cancer recurrence after treatment.

• Components:
  • Collection of a blood sample from the patient.
  • Analysis of serum using ELISA or CLIA to measure Cyfra 21-1 levels.
  • Calibration with standard controls to ensure accuracy.
  • Reporting of Cyfra 21-1 concentration in nanograms per millilitre (ng/mL).
• Procedure:
  • Blood is drawn from the patient and the serum is separated.
  • The serum is subjected to immunoassay techniques to measure Cyfra 21-1 levels.
  • Results are compared to established reference ranges to determine if levels are elevated.

• Normal Findings: Cyfra 21-1 levels are within the normal reference range (typically <3.3 ng/mL, but may vary by lab), suggesting a low likelihood of NSCLC.
• Elevated Levels: Cyfra 21-1 levels above the reference range indicate a higher likelihood of NSCLC or other conditions, warranting further diagnostic evaluation.
• Prognostic Implications: Higher levels of Cyfra 21-1 are often associated with more advanced lung cancer and may indicate a poorer prognosis.
• Clinical Correlation: Results should be interpreted in conjunction with other clinical findings, imaging studies, and biopsy results.

• Qualitative and Quantitative: The test provides a quantitative measurement of Cyfra 21-1 levels in the serum.
• Interpretation: Results are interpreted based on the concentration of Cyfra 21-1, with higher values suggesting the presence or progression of lung cancer.
• Report: A detailed report is generated, including the Cyfra 21-1 level and its clinical significance.
• Turnaround Time: Typically 1-3 days, depending on the laboratory.

Q. What is the Cyfra 21-1 Lung Cancer Marker Serum Test?
This test measures the level of Cyfra 21-1, a protein fragment elevated in the blood of patients with non-small cell lung cancer (NSCLC)
 

Q. Why is the Cyfra 21-1 Lung Cancer Marker Serum Test ordered?
It is ordered to help diagnose lung cancer, monitor treatment effectiveness, and detect disease recurrence in patients with NSCLC
 

Q. How is the Cyfra 21-1 Lung Cancer Marker Serum Test performed?
A blood sample is taken, and the serum is tested using immunoassay techniques like ELISA or CLIA to measure Cyfra 21-1 levels
 

Q. What do elevated Cyfra 21-1 levels indicate?
Elevated Cyfra 21-1 levels may indicate the presence of non-small cell lung cancer, particularly if levels are significantly above the normal range
 

Q. Can Cyfra 21-1 levels be elevated for reasons other than lung cancer?
Yes, Cyfra 21-1 levels can also be elevated in other conditions, such as certain other cancers or benign lung diseases, so results should be interpreted in context
 

Q. Is any preparation needed for the Cyfra 21-1 Lung Cancer Marker Serum Test?
No special preparation is required, but it's important to inform your healthcare provider of any medications or conditions that might affect the results
 

Q. How long does it take to get results from the Cyfra 21-1 Lung Cancer Marker Serum Test?
Results are typically available within 1-3 days after the blood sample is collected.